MetLife Investment Management’s Vanda Pharmaceuticals VNDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $187K | Buy |
30,563
+515
| +2% | +$3.36K | ﹤0.01% | 2450 |
|
|
2026
Q1 | $208K | Buy |
30,048
+5,638
| +23% | +$43.5K | ﹤0.01% | 2208 |
|
|
2025
Q4 | $215K | Sell |
24,410
-7,899
| -24% | -$43.5K | ﹤0.01% | 2238 |
|
|
2025
Q3 | $161K | Sell |
32,309
-551
| -2% | -$2.55K | ﹤0.01% | 2428 |
|
|
2025
Q2 | $155K | Buy |
32,860
+44
| +0.1% | +$192 | ﹤0.01% | 2314 |
|
|
2025
Q1 | $151K | Buy |
32,816
+5,210
| +19% | +$24.3K | ﹤0.01% | 2337 |
|
|
2024
Q4 | $132K | Sell |
27,606
-5,482
| -17% | -$26.3K | ﹤0.01% | 2501 |
|
|
2024
Q3 | $155K | Hold |
33,088
| – | – | ﹤0.01% | 2419 |
|
|
2024
Q2 | $187K | Buy |
33,088
+3,324
| +11% | +$17.2K | ﹤0.01% | 2292 |
|
|
2024
Q1 | $122K | Sell |
29,764
-837
| -3% | -$3.35K | ﹤0.01% | 2446 |
|
|
2023
Q4 | $129K | Hold |
30,601
| – | – | ﹤0.01% | 2479 |
|
|
2023
Q3 | $132K | Hold |
30,601
| – | – | ﹤0.01% | 2439 |
|
|
2023
Q2 | $202K | Hold |
30,601
| – | – | ﹤0.01% | 2272 |
|
|
2023
Q1 | $208K | Hold |
30,601
| – | – | ﹤0.01% | 2197 |
|
|
2022
Q4 | $226K | Hold |
30,601
| – | – | ﹤0.01% | 2178 |
|
|
2022
Q3 | $302K | Hold |
30,601
| – | – | ﹤0.01% | 2018 |
|
|
2022
Q2 | $334K | Hold |
30,601
| – | – | ﹤0.01% | 1950 |
|
|
2022
Q1 | $346K | Buy |
30,601
+10,989
| +56% | +$144K | ﹤0.01% | 2006 |
|
|
2021
Q4 | $308K | Buy |
19,612
+3,281
| +20% | +$57.2K | ﹤0.01% | 1798 |
|
|
2021
Q3 | $280K | Sell |
16,331
-5,053
| -24% | -$88.5K | ﹤0.01% | 1865 |
|
|
2021
Q2 | $460K | Hold |
21,384
| – | – | ﹤0.01% | 1618 |
|
|
2021
Q1 | $321K | Sell |
21,384
-2,952
| -12% | -$47.8K | ﹤0.01% | 1775 |
|
|
2020
Q4 | $320K | Hold |
24,336
| – | – | ﹤0.01% | 1728 |
|
|
2020
Q3 | $235K | Hold |
24,336
| – | – | ﹤0.01% | 1766 |
|
|
2020
Q2 | $278K | Hold |
24,336
| – | – | ﹤0.01% | 1701 |
|
|
2020
Q1 | $252K | Hold |
24,336
| – | – | ﹤0.01% | 1572 |
|
|
2019
Q4 | $399K | Hold |
24,336
| – | – | ﹤0.01% | 1581 |
|
|
2019
Q3 | $323K | Hold |
24,336
| – | – | ﹤0.01% | 1659 |
|
|
2019
Q2 | $343K | Sell |
24,336
-48,672
| -67% | -$775K | ﹤0.01% | 1713 |
|
|
2019
Q1 | $1.34M | Buy |
73,008
+48,672
| +200% | +$1.11M | ﹤0.01% | 1487 |
|
|
2018
Q4 | $636K | Hold |
24,336
| – | – | 0.01% | 1219 |
|
|
2018
Q3 | $559K | Hold |
24,336
| – | – | 0.01% | 1466 |
|
|
2018
Q2 | $464K | Buy |
24,336
+4,063
| +20% | +$67.9K | 0.01% | 1446 |
|
|
2018
Q1 | $342K | Hold |
20,273
| – | – | ﹤0.01% | 1609 |
|
|
2017
Q4 | $308K | Buy |
+20,273
| New | +$301K | ﹤0.01% | 1694 |
|
Other funds holding VNDA
ACM
MetLife Investment Management's VNDA Position: Q2 2026 in Review
MetLife Investment Management increased its Vanda Pharmaceuticals (VNDA) stake by 1.7% in Q2 2026, buying an estimated $3.36K and bringing the position to 30,563 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #2450.
MetLife Investment Management first reported a position in VNDA in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.34M in Q1 2019. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.
- MetLife Investment Management held 30,563 shares of Vanda Pharmaceuticals worth $187K as of Q2 2026.
- MetLife Investment Management bought 515 Vanda Pharmaceuticals shares in Q2 2026, an estimated $3.36K.
- Vanda Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2450 holding.
- MetLife Investment Management first reported a position in Vanda Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Vanda Pharmaceuticals position peaked at $1.34M in Q1 2019.
- 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.